Latest news newssearch boxGO All Ad hoc Other 03 Oct 2022 Idorsia Japan announces positive results with daridorexant in a Phase 3 study of Japanese patients with insomnia 27 Sep 2022 Idorsia secures additional cash by entering into a building sale and leaseback agreement 26 Jul 2022 Idorsia announces financial results for the first half 2022 – reaching commercial stage 23 May 2022 Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension 10 May 2022 Phase 2a study results in binge eating disorder 03 May 2022 Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder 02 May 2022 Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia 26 Apr 2022 Idorsia announces financial results for the first quarter 2022 – first product launched, second in the starting blocks 20 Apr 2022 PIVLAZ (clazosentan) – Idorsia’s first commercial product – now available for patients in Japan 14 Apr 2022 Idorsia holds its Annual General Meeting of Shareholders 04 Apr 2022 The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage 10 Mar 2022 New data for daridorexant in patients with insomnia disorder – including long-term safety and efficacy – to be presented at World Sleep 2022 03 Mar 2022 Idorsia issues Notice of the 2022 Annual General Meeting of Shareholders 25 Feb 2022 QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder 08 Feb 2022 Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025 26 Jan 2022 Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada 24 Jan 2022 Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development 20 Jan 2022 Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg 20 Jan 2022 The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia 12 Jan 2022 Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep 1 2 3 4 5 6 7